Carna Biosciences, Inc. Carna Biosciences is a clinical-stage biopharmaceutical company founded in April 2003 in Kobe, Japan to discover and develop innovative therapies to treat serious unmet medical needs, focusing on small molecule drugs, mainly targeting kinases
Carna Health - Raising Awarenesss. Promoting Prevention. Carna Health provides decision support resources while also upskilling resource-restrained healthcare environments From the onset, providers are equipped with a integrated point-of-care disease identification technology, educational resources for patients, and care pathway automation tool
About Us - Carna Biosciences, Inc. “Carna” – an ancient Roman Goddess – was the guardian of the heart and the vital parts of the human body With her expectant yet determined look and hair made of protein kinases, our Goddess Carna was envisaged to represent what we need to achieve as a biotechnology company
Càrna - Wikipedia Carna is thought to be more fertile than its neighbour, Oronsay, and due to its much greater aspect has better water sources There are signs of terracing by early man and the northern part of the island is named Bac a' Mhathachaidh (Scottish Gaelic: "cultivated bank")
Carna Health Is Taking on the Chronic Kidney Disease Crisis Carna Health is a digital health company at the forefront of chronic disease innovation, merging a unique platform integrated with point-of-care technology with a deep commitment to global patient care to provide meaningful transformation for chronic disease, starting with chronic kidney disease
Carna Medical: Leading Medical Aesthetic Equipments From acne and hyperpigmentation to fine lines and wrinkles, Carna Plasma Technology offers a comprehensive solution that caters to the diverse needs of individuals seeking to enhance their skin’s health and appearance
Carna Health - News Carna Health Announces Promising Results from Cameroon Pilot Program Aimed at Slowing Progression of Chronic Kidney Disease Read more
Carna Biosciences, Inc. (4572. T) - Yahoo Finance Description Carna Biosciences, Inc , a clinical-stage biopharmaceutical company, discovers and develops drug therapies to treat unmet medical needs in Japan
Sofnobrutinib - Drug Targets, Indications, Patents - Synapse Now, its global highest R D status is Phase 1, Mechanism: BTK inhibitors (Tyrosine-protein kinase BTK inhibitors), Therapeutic Areas: Other Diseases, Active Indication: Inflammation, Active Org : Carna Biosciences, Inc
All Protein Product List - Carna Biosciences, Inc. Carna offers an expanded portfolio of high purity, active recombinant human proteins All of our protein products are developed and produced entirely in-house from gene cloning, expression in insect cells or E Coli, and purification, and undergo rigorous quality control